Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) SVP Bosch John Roderick Ten sold 2,834 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $113.17, for a total transaction of $320,723.78. Following the completion of the transaction, the senior vice president owned 16,551 shares in the company, valued at $1,873,076.67. This trade represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Monday, October 5th, Bosch John Roderick Ten sold 2,834 shares of Billiontoone stock. The shares were sold at an average price of $105.15, for a total transaction of $297,995.10.
- On Thursday, September 24th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00.
- On Monday, September 21st, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $106.61, for a total transaction of $150,959.76.
- On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64.
- On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total value of $141,700.00.
- On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $131,582.62.
Billiontoone Trading Up 3.1%
NASDAQ BLLN opened at $113.89 on Thursday. The stock has a market capitalization of $5.37 billion and a P/E ratio of 162.70. The business has a 50 day simple moving average of $104.67 and a 200 day simple moving average of $96.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44.
Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. Research analysts expect that Billiontoone, Inc. will post 0.80 earnings per share for the current year.
Key Stories Impacting Billiontoone
Here are the key news stories impacting Billiontoone this week:
- Positive Sentiment: Q3 results topped expectations: Revenue was about $123.0 million, above the $115.8 million FactSet estimate. Reported earnings per share also exceeded the $0.16 consensus, although sources cite different actual EPS figures ($0.32 and $0.48). BillionToOne Q3 results and guidance
- Positive Sentiment: Higher 2026 revenue guidance: The company raised its full-year revenue outlook, signaling improved expectations for growth. Company announcement
- Negative Sentiment: Multiple insiders sold shares: The CEO, CTO and an SVP reported sales. The transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but do not eliminate—the bearish signal investors could take from insider selling. Insider transaction reports
Hedge Funds Weigh In On Billiontoone
Institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new stake in Billiontoone during the second quarter worth about $29,000. Parallel Advisors LLC boosted its stake in Billiontoone by 86.7% in the third quarter. Parallel Advisors LLC now owns 280 shares of the company's stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Family Legacy Financial Solutions LLC bought a new position in shares of Billiontoone during the 3rd quarter valued at approximately $53,000. MCF Advisors LLC increased its stake in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company's stock worth $54,000 after purchasing an additional 344 shares during the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new stake in shares of Billiontoone during the 3rd quarter worth approximately $56,000.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. BTIG Research cut their target price on shares of Billiontoone from $142.00 to $130.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Guggenheim upped their price objective on shares of Billiontoone from $125.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Weiss Ratings cut Billiontoone from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, October 8th. Finally, Zacks Research raised shares of Billiontoone from a "strong sell" rating to a "hold" rating in a research note on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Billiontoone has an average rating of "Moderate Buy" and a consensus target price of $126.25.
Check Out Our Latest Research Report on BLLN
Billiontoone Company Profile
(
Get Free Report)
BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company's technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.
The company's products include prenatal diagnostic and screening solutions marketed under the UNITY brand.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
